Mr. Cunningham, Founder and Principal at Innovations for Global Health
(iGH), has 23 years of experience in the pharmaceutical and global health space. He has worked in the vaccine arena for the past 16 years, and led the new vaccine planning function at Merck. He established iGH to support the assessment, acceleration, introduction and execution of global health innovations, guided by the belief that such innovations can significantly improve public health outcomes in low- and middle-income countries. Mr. Cunningham leads iGH’s support for GHIF as a Senior Advisor to the Fund.
Mr. Cunningham spent more than three years working at the Bill & Melinda Gates Foundation (BMGF) where he supported the HIV, TB and Malaria program teams, and worked closely with a range of partners including multi-national corporations, emerging market manufacturers, WHO, UNICEF, Gavi and others to support delivery of new vaccines and the eradication of polio.
In addition, while at BMGF, he negotiated a number of partnerships to drive access to new vaccines. He was responsible for assessments of new technologies for IPV to support polio eradication as well as partner/supplier assessments including leadership of technical, financial and legal diligence efforts for multiple manufacturers.
Mr. Cunningham has an MA (Engineering) and an M. Eng. (Manuf. Engineering) degree from Cambridge University, in addition to an MBA (Marketing & International Business) from the University of Michigan.